Trial Profile
Disposition of [14C]-LY2157299 Monohydrate Following Oral Administration in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2013
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary)
- Indications Glioblastoma; Glioma; Liver cancer; Pancreatic cancer; Solid tumours
- Focus Pharmacokinetics
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2013 New trial record